Virtues of being faithful: Can we limit the genetic variation in human immunodeficiency virus?

Journal of Molecular Medicine

Volumn 76, Issue 9, 1998, Pages 604-612

  Drosopoulos, William C ^a,c   Rezende, Lisa F ^a   Wainberg, Mark A ^b   Prasad, Vinayaka R ^a,d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c NEW YORK UNIVERSITY   (United States)

^d INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Escape mutants; Fidelity; Genetic variation; HIV AIDS

Indexed keywords

GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; PATHOGENESIS; REVIEW; VIRAL GENETICS; VIRUS REPLICATION;

DRUG RESISTANCE, MICROBIAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; VARIATION (GENETICS);

EID: 0031831625     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090050257     Document Type: Review

References (83)

1. Saag MS, Hahn BH, Gibbons J, Li Y, Parks ES, Parks WP, Shaw GM (1988) Extensive variation of human immunodeficiency virus type-1 in vivo. Nature 334:440-444
2. Meyerhans A, Cheynier R, Albert J, Seth M, Kwok S, Sninsky J, Morfeldt-Manson L, Asjo B, Wain-Hobson S (1989) Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell 58:901-910
3. Hahn BH, Shaw GM, Taylor ME, Redfield RR, Markham PD, Salahuddin SZ, Wong-Staal F, Gallo RC, Parks ES, Parks WP (1986) Genetic variation in HTLV III/LAV over time in patients with AIDS or at risk for AIDS. Science 232:1548-1553
4. Pang S, Shlesinger Y, Daar ES, Moudgil T, Ho DD, Chen I SY (1992) Rapid generation of sequence variatioon during primary HIV-1 infection. AIDS 6:453-460
5. Drosopoulos WC, Prasad VR (1996) Increased polymerase fidelity of E89G, a nucleoside analog-resistant variant of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. J Virol 70:4834-4838
6. Pandey VN, Kaushik N, Rege N, Sarafianos SG, Yadav PNS, Modak MJ (1996) Role of methionine 184 in human immunodeficiency virus type 1 reverse transcriptase in the polymerase function and fidelity of DNA synthesis. Biochemistry 35:2168-2179
7. Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak MA, Gu Z, Song Q, Manne J, Islam S, Castriota G, Prasad VR (1996) Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 271:1282-1285
8. Rubinek T, Bakhanashvili M, Taube R, Avidan O, Hizi A (1997) The fidelity of 3' misinsertion and mispair insertion during DNA synthesis exhibited by two drug-resistant mutants of the reverse transcriptase of human immunodeficiency virus type I with Leu74Val and Glu89Gly. Eur J Biochem 247:238-247
9. Prasad VR, Drosopoulos WC, Hamburgh ME (1996) Approaches to control drug resistance in HIV: the role of increased polymerase fidelity. AIDS Res Hum Retroviruses 12:959-963
10. Jeon CJ, Agarwal K (1996) Fidelity of RNA polymerase II transcription controlled by elongation factor TFIIS. Proc Natl Acad Sci USA 93:13677-13682
11. Erie DA, Hajiseyedjavadi O, Young MC, von Hippel PH (1993) Multiple RNA polymerase conformations and GreA: control of the fidelity of transcription. Science 262:867-873
12. Preston BD, Garvey N (1992) Retroviral mutation and reverse transcriptase fidelity. Pharm Techol 16:34-52
13. Preston BD, Dougherty JP (1996) Mechanisms of retroviral mutation. Trends Microbiol 4:16-21
14. Preston BD, Poiesz BJ, Loch LA (1988) Fidelity of HIV-1 reverse transcriptase. Science 242:1168-1171
15. Perrino FW, Preston BD, Sandell LE, Loeb LA (1989) Extension of mismatched 3' termini of DNA is a major determinant of the infidelity of human immunodeficiency virus type 1 reverse transcriptase. Proc Natl Acad Sci USA 86:8343-8347
16. Roberts JD, Bebenek K, Kunkel TA (1988) The accuracy of reverse transcriptase from HIV-1. Science 242:1171-1173
17. Ricchetti M, Buc H (1990) Reverse transcriptases and genomic variability: the accuracy of DNA replication is enzyme specific and sequence dependent. EMBO J 9:1583-1593
18. Bebenek K, Abbotts J, Wilson SH, Kunkel TA (1993) Error-prone polymerization by HIV-1 reverse transcriptase. J Biol Chem 268:10324-10334
19. Yu H, Goodman MF (1992) Comparison of HIV-1 and Avian myeloblastosis virus reverse transcriptase fidelity on RNA and DNA templates. J Biol Chem 267:10888-10896
20. Boyer JC, Bebenek K, Kunkel TA (1992) Unequal human immunodeficiency virus type 1 reverse transcriptase error rates with RNA and DNA templates. Proc Natl Acad Sci USA 89:6919-6923
21. Mansky LM, Temin M (1995) Lower In vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69:5087-5094
22. Meyerhans A, Vartanian JP, Hultgren C, Plikat U, Karlsson A, Wang L, Eriksson S, Wain-Hobson S (1994) Restriction and enhancement of human immunodeficiency virus type I replication by modulation of intracellular deoxynucleoside triphosphate pools. J Virol 68:535-540
23. Back NKT, Nijhuis M, Keulen W, Boucher CAB, Oude Essink BB, van Kuilenburg ABP, van Gennip AH, Berkhout B (1996) Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect in the reverse transcriptase enzyme. EMBO J 15:4040-4049
24. Gao WY, Cara A, Gallo RC, Lori F (1993) Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 90:8925-8928
25. Lori F, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewicz J, Gallo RC (1994) Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 266:801-805
26. Lori F, Gallo RC (1995) Hydroxyurea and AIDS: an old drug finds a new application? AIDS Res Hum Retroviruses 11: 1149-1151
27. Vartanian JP, Plikart U, Henry M, Mahieux R, Guillemot L, Meyerhans A, Wain-Hobson S (1997) HIV genetic variation is directed and restricted by DNA precursor availability. J Mol Biol 270:139-151
28. Vartanian JP, Meyerhans A, Asjo B, Wain-Hobson S (1991) Selection, recombination, and G to A hypermutation of human immunodeficiency virus type 1 genome. J Virol 65:1779-1788
29. Pathak VK, Temin H (1990) Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: substitutions, frameshifts, and hypermutations. Proc Natl Acad Sci USA 87:6019-6023
30. Fitzgibbon JE, Mazar S, Dubin DT (1993) A new type of G→A hypermutation affecting human immunodeficincy virus. AIDS Res Hum Retroviruses 9:833-838
31. Elder JH, Lerner DL, Hasselkus-Light CS, Fontenot DJ, Hunter E, Luciw PA, Montelaro RC, Phillips TR (1992) Distinct subsets of retroviruses encode dUTPase. J Virol 66:1791-1794
32. Lerner DL, Wagaman PC, Phillips TR, Prospero-Garcia O, Henriksen SJ, Fox HS, Bloom FE, Elder JH (1995) Increased mutation frequency of feline immunodeficiency virus lacking functional deoxyuridine-triphosphatase. Proc Natl Acad Sci USA 92:7480-7484
33. Bouhamdan M, Benichou S, Rev F, Navurro JM, Agostini I, Spire B, Camonis J, Slupphaug G, Vigne R, Benarous R, Sire J (1996) Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA alycosylase DNA repair enzyme. J Virol 70:697-704
34. Mansky LM (1996) The mutation rate of human immunodeficiency virus type 1 is influenced by the vpr gene. Virology 222:391-400
35. Temin HM (1993) Retrovirus variation and reverse transcription: abnormal transfers result in retrovirus genetic variation. Proc Natl Acad Sci USA 90:6900-6903
36. Peliska JA, Benkovic SJ (1992) Mechanism of DNA strand transfer reactions catalyzed by HIV-1 reverse transcriptase. Science 258;1112-1118
37. Peliska JA, Benkovic SJ (1994) Fidelity of in vitro DNA strand transfer reactions catalyzed by HIV-1 reverse transcriptase. Biochemistry 33:3890-3895
38. Wu W, Palaniappan C, Bambara RA, Fay PJ (1996) Differences in mutagenesis during minus strand, plus strand and strand transfer (recombination) synthesis of the HIV-1 nef gene in vitro. Nucleic Acids Res 24:1710-1718
39. Wu W, Blumberg BM, Fay PJ, Bambara RA (1995) Strand transfer mediated by human immunodeficiency virus reverse transcriptase in vitro is promoted by pausing and results in misincorporation. J Biol Chem 270:325-332
40. Patel PH, Preston BD (1994) Marked infidelity of human immunodeficiency virus type 1 reverse transcriptase at RNA and DNA template ends. Proc Natl Acad Sci USA 91:549-553
41. Kellam P, Larder BA (1995) Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance. J Virol 69:669-674
42. Moutouh L, Corbeil J, Richman DD (1996) Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. Proc Natl Acad Sci USA 93:6106-6111
43. Robertson DL, Hahn BH, Sharp PM (1995) Recombination in AIDS viruses. J Mol Evol 40:249-259
44. Robertson DL, Sharp PM, McCutchan FE, Hahn BH (1995) Recombination in HIV. Nature 374:124-126
45. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126
46. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586
47. Wolinsky SM, Korber BT, Neumann AU, Daniels M, Kunstman KJ, Whetsell AJ, Furtado MR, Cao Y, Ho DD, Safrit JT, Koup RA (1996) Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 272:537-542
48. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS, Shaw GM (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122
49. Coffin JM (1995) HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 267:483-489
50. Delassus S, Cheynier R, Wain-Hobson S (1992) Nonhomogeneous distribution of human immunodeficiency virus type 1 proviruses in the spleen. J Virol 66:5642-5645
51. Cheynier R, Henrichwark S, Hadida F, Pelletier E, Oksenhendler E, Autran B, Wain-Hobson S (1994) HIV and T cell expansion in splenic white pulps is accompanied by infiltration of HIV-specific cytotoxic T lymphocytes. Cell 78:373-387
52. Cheynier R, Henrichwark S, Hadida F, Pelletier E, Oksenhendler E, Autran B, Wain-Hobson S (1995) Clonal expansion of T cells and HIV genotypes in microdissected splenic white pulps indicates viral replication in situ and infiltration of HIV-specifrc cytotoxic T lymphocytes. Adv Exp Med Biol 374:173-182
53. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goude REY, van Steenwijk RP, Lange JMA, Eeftink Schattenkerk JKM, Miedema F, Tersmette M (1992) Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. J Virol 66:1354-1360
54. Tersmette M, Gruters RA, De Wolf F, de Goede REY, Lange JMA, Schellekens PTA, Goudsmit J, Huisman JG, Miedema F (1989) Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome obtained from studies on a panel of sequential HIV isolates. J Virol 63:2118-2125
55. McKnight A, Clapham PR (1995) Immune escape and tropism of HIV. Trends Microbiol 3:356-361
56. Watkins BA, Reitz MSJ, Wilson CA, Aldrich K, Davis AE, Robert-Guroff M (1993) Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways. J Virol 67:7493-7500
57. McKeating JA, Gow J, Goudsmit J, Pearl LH, Mulder C, Weiss RA (1989) Characterization of HIV-1 neutralization escape mutants. AIDS 3:777-784
58. Arendrup M, Nielsen C, Hansen JE, Pedersen C, Mathiesen L, Nielsen JO (1992) Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies. J AIDS 5:303-307
59. Gorny MK, Conley AJ, Karwowska S, Buchbinder A, Xu JY, Emini EA, Koenig S, Zolla-Pazner S (1992) Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol 66:7538-7542
60. Fung MS, Sun CR, Gordon WL, Liou RS, Chang TW, Sun WN, Daar ES, Ho DD (1992) Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J Virol 66:848-856
61. Koenig S, Earl P, Powell D, Pantaleo G, Merli S, Moss B, Fauci AS (1988) Group-specific, major histocompatibility complex class !-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1-infected individual. Proc Natl Acad Sci USA 85:8638-8642
62. Lanzavecchia A, Roosnek E, Gregory T, Berman P, Abrignani S (1988) T cells can present antigens such as HIV gp120 targeted to their own surface molecules. Nature 334:530-532
63. Cann AJ, Churcher MJ, Boyd M, O'Brien W, Zhuo J-Q, Zack J, Chen I SY (1992) The region of the envelope gene of human immunodeficiency virus type 1 responsible for determination of cell tropism. J Virol 66:305-309
64. Hwang SS, Boyle TJ, Lyerly HK, Cullen BR (1991) Identification of envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 253:71-74
65. McKnight A, Weiss RA, Shotton C, Takeuchi Y, Hoshino H, Clapham PR (1995) Change in tropism upon immune escape by human immunodeficiency virus. J Virol 69:3167-3170
66. Richman DD (1992) HIV drug resistance. AIDS Res Hum Retroviruses 8:1065-1071
67. Jacobsen H, Haenggi M, Ott M, Duncan IB, Andreoni M, Vella S, Mous J (1996) Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials. Antiviral Res 29:95-97
68. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, Markowitz M, Chernyavskiy T, Niu P, Lyons N, Hsu A, Granneman GR, Ho DD, Boucher CA, Leonard JM, Norbeck DW, Kempf DJ (1996) Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 2:760-766
69. Perrin L, Hirschel B (1996) Combination therapy in primary HIV infection. Antiviral Res 29:87-89
70. Johnson VA (1996) Combination therapy for HIV-1 infection-overview: preclinical and clinical analysis of antiretroviral combinations. Antiviral Res 29:35-39
71. Collier AC, Coombs RW, Schoenfeld DA, Bassett R, Baruch A, Corey L (1996) Combination therapy with zidovudine, didanosine and saquinavir. Antiviral Res 29:99
72. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ, Friedman HM, Merigan TC, Reichman RC, Hooper C, Corey L (1996) Treatment of human immunodeficiency virus infection (HIV) with saquinavir, zidovudine and zalcilabine. AIDS Clinical Trials Group. N Engl J Med 334:1011-1017
73. Paul WE (1995) Can the immune response control HIV infection? Cell 82:177-182
74. Haynes BF, Pantaleo G, Fauci AS (1996) Toward an understanding of the correlates of protective immunity to HIV infection. Science 271:324-328
75. Coffin JM (1996) HIV viral dynamics. AIDS 10 [Suppl 3]:S75-S84
76. Lafeuillade A, Tamalet C, Poogi C, Kaplanski, Chouraqui M, Delbeke E, Profizi N, Kaplanski S, Farnarier C (1997) Four-drug combination: effect of viral load and immune reconstitution (blood and lymph nodes). 4th Conference on Retroviruses and Opportunistic Infections, Washington, abstract 235
77. Perrin L, Markowitz M, Calandra G, Chung M (1997) MRL acute HIV infection study Group. An open treatment study of acute HIV infection with zidovudine, lamivudine and indinavir sulfate. 4th Conference on Retroviruses and Opportunistic Infections, Washington, abstract 238
78. Inouye P, Zolfa-Pazner S, Wainberg MA (1997) Neutralizing antibody directed against the V3 loop selects for different escape variants in M184V-containing virus compared with wild type HIV-1. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, 25-28 June, St. Petersburg, Florida, abstract 118
79. Oude Essink BB, Back NKT, Berkhout B (1997) Increased polymerase fidelity of the 3TC-resistant variants of HIV-1 reverse transcriptase. Nucleic Acids Res 25:3212-3217
80. Hsu M, Inouye P, Rezende L, Richard N, Li Z, Prasad VR, Wainberg MA (1997) Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1. Nucleic Acids Res 25:4532-4536
81. Larder BA, Kemp SD, Harrigan PR (1995) Potential mechanism for sustained anti-retroviral efficacy of 3TC-AZT combination therapy. Science 269:696-699
82. Eron JJ, Benoit SL, Jemsek J, Mac-Arthur RD, Santana J, Quinn JB, Kuritzkes DR, Fallon MA, Rubin M, North American HIV Working Party (1995) Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 333:1662-1669
83. Schooley RT, Ramirez-Ronda C, Lange JM, Cooper DA, Lavelle J, Lefkowitz L, Moore M, Larder BA, St. Clair M, Mulder JW, McKinnis R, Pennington KN, Harrigan PR, Kinghorn I, Steel H, Rooney JF, Wellcome Resistance Study Collaborative Group (1996) Virologie and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. J Infect Dis 173:1354-1366